AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 61 min read$ARTV

Horan Christopher sold $71K of ARTV

Horan Christopher (Chief Tech Operations Officer) sold 10,340 shares of Artiva Biotherapeutics, Inc. (ARTV) at $6.84 on 2026-10-05.

Original reporting
SEC EDGAR · Horan Christopher
Published Oct 6, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock, but it provides transparency for investors.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical trial milestones for Artiva that could outweigh the small sell‑off.

Relevance 3/10Novelty 3/10Timing: filed today (Oct 6)

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Chief Tech Operations Officer sold 10,340 shares for $70,696, reducing his stake to 312,744 shares.

Expected impact

likely slight downward pressure as market prices in the insider sale.

Evidence & confidence

The transaction is small relative to market cap and does not materially affect supply‑demand dynamics.

Market effects

Sector

No broader sector impact; biotech sector unchanged.

Regional

U.S. market only; no regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

If the insider is privy to upcoming positive news, the sale could be a temporary liquidity move, not a bearish signal.

Key entities

  • company
    Artiva Biotherapeutics, Inc.

    Biotech firm developing gene‑therapy products.

  • person
    Horan Christopher

    Chief Tech Operations Officer at Artiva.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARTV insider trading history →

Related articles

OCT 27
$ARTVLow

Artiva Biotherapeutics, Inc. (ARTV): Results of Operations and Financial Condition

Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® • Company halting further development of AlloNK ® (AB-101), including the planned phase 3 pivotal trial • Updated deep B cell depletion and clinical response data is consistent

SEC EDGAR 8-K2 min
OCT 27
$ARTVHighAI 8/10

Why is Artiva Biotherapeutics stock collapsing today?

Artiva Biotherapeutics' stock fell 30% after halting AlloNK (AB-101) development due to safety events and poor clinical data. The company plans to cut 94% of its workforce and explore strategic alternatives, including liquidation. CEO and COO sold shares before the announcement. Artiva had $319.1M in cash as of September 30. The stock traded at $4.31, far below its 52-week high of $14.53.

investing.com2 min